$2bn deal sees uniQure license haemophilia B gene therapy to...

UniQure has signed a deal that could be worth over $2 billion with CSL Behring – giving the company exclusive global rights to uniQure’s gene therapy for haemophilia B. 

UniQure presses go on Huntington’s gene therapy trial

Catalyst’s rival to NovoSeven hits the mark in phase 2 haemo...

uniQure presses 'refresh' on haemophilia gene therapy, gets ...

Biotech has been in talks with US and EU regulators

Submission completed, Spark sets sight on first ever US gene...

Spark Therapeutics has completed the rolling submission of gene therapy product voretigene neparvovec, for patients with a rare genetic form of blindness.

Glybera, the most expensive drug in the world, to be withdra...

Glybera, the gene therapy which is the most expensive drug in the world, is to be with